MENU

PYPD PolyPid Ltd Forecast, Technical & Fundamental Analysis

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology... Show more

A.I.Advisor
Nov 12, 2026

PolyPid Ltd. (PYPD) Stock Forecast: The FDA Decision That Could Define Its Commercial Future

Key Takeaways

  • Regulatory inflection point: D-PLEX100, PolyPid's lead candidate for preventing surgical site infections (SSIs), is under U.S. Food and Drug Administration (FDA) Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of November 28, 2026 — a near-term catalyst that could reshape the company's risk profile.
  • Commercial readiness: A partnership with Azurity secured roughly $30 million in upfront and near-term funding plus more than $290 million in contingent milestones and royalties, positioning PolyPid for a potential U.S. launch targeted for early 2027.
  • Strategic positioning: The company's proprietary PLEX (Polymer-Lipid Encapsulation MatriX) delivery technology underpins a pipeline beyond D-PLEX100, including OncoPLEX (preclinical oncology) and a diabetic-foot-infection program, PD01B.
  • Macro and financing sensitivity: As a clinical-stage biotech, PolyPid remains exposed to interest-rate-driven financing conditions, dilution risk, and dependence on milestone payments to extend its cash runway.
  • Analyst stance: Sell-side consensus is generally constructive, with multiple firms rating the stock a Buy and average twelve-month price targets well above recent trading levels.
  • Key risks: Regulatory or manufacturing-inspection setbacks, slower-than-expected commercial uptake, and reliance on a partner for launch execution could all alter the outlook.
  • For additional detail, explore PolyPid's Major News, Today's Price Move, Price Targets, and Earnings pages.
  • For AI-driven trading insights across a wide range of tickers, explore Trending AI Robots.

Strategic Positioning and Competitive Outlook

PolyPid occupies a differentiated niche within the biotechnology sector through its PLEX technology, a polymer-lipid encapsulation matrix designed to deliver drugs locally and release them over prolonged, pre-determined periods. This localized, sustained-release approach targets a meaningful unmet need: reducing surgical site infections (SSIs) after abdominal colorectal surgery, a complication that raises costs, prolongs hospital stays, and burdens patients.

Its medium-term positioning hinges on converting D-PLEX100 from a late-stage asset into a commercial product. An accepted New Drug Application (NDA) under Priority Review signals that the FDA recognized the program's potential to address an area of significant unmet need. The commercial agreement with Azurity provides a partner-led route to market, allowing PolyPid to leverage established commercial infrastructure rather than building a costly salesforce from scratch — a structure that could improve cost efficiency if approval is secured.

Beyond its lead asset, the pipeline adds optionality. OncoPLEX represents an early-stage oncology application of the same delivery platform, while PD01B extends the franchise into diabetic foot infections, with pre-IND (Investigational New Drug) and first-in-human work targeted for the second half of 2027. A research collaboration with ImmunoGenesis further applies the platform to solid-tumor formulations. This platform breadth is a structural strength, though it remains unproven at commercial scale.

Major Catalysts Ahead

The dominant near-term catalyst is the FDA's decision on D-PLEX100, expected around the November 28, 2026 PDUFA date. An approval would transition PolyPid toward first commercial revenue and trigger additional milestone economics under the Azurity agreement; a Complete Response Letter or manufacturing-inspection delay would materially reset expectations.

A planned European Medicines Agency (EMA) submission represents a second regulatory avenue that could broaden the addressable market. On the pipeline front, progress on PD01B toward pre-IND and first-in-human milestones in the second half of 2027 provides a longer-dated value driver.

Analyst sentiment has trended constructive. H.C. Wainwright maintained a Buy rating with a $13 price target, Roth MKM reiterated Buy at $8, Oppenheimer initiated coverage with a Buy rating and $10 target in late October 2026, and Craig-Hallum maintained a Buy while adjusting its target to $12. Consensus data aggregated by S&P Global point to a "Strong Buy" rating and an average twelve-month price target of approximately $11.4, with estimates ranging from roughly $8 to $14. The direction of these targets suggests that coverage has remained largely favorable as regulatory milestones approach, though the spread between low and high targets reflects genuine uncertainty about commercial execution.

Industry and Macroeconomic Forces

PolyPid's trajectory is shaped by the broader biotech financing environment. Interest rates directly influence the cost and availability of capital for pre-revenue companies, affecting both equity dilution and the terms of any future financing. While PolyPid narrowed its third-quarter net loss and received a $15 million milestone in October 2026, its cash balance remains modest, making milestone inflows and prudent capital allocation central to its runway.

Within healthcare, trends remain broadly supportive of innovation in surgical care and infection prevention, given hospital incentives to reduce readmissions and complication-related costs. However, the regulatory climate — including FDA review timelines and inspection outcomes — and pricing or reimbursement dynamics for hospital-administered products will shape commercial uptake. Geopolitical considerations are also relevant: as an Israel-headquartered company, PolyPid's operations and personnel can be influenced by regional stability, a factor investors weigh alongside clinical and commercial fundamentals.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For those seeking an additional, data-driven lens on names like PYPD, exploring the Trend Prediction Engine can complement fundamental and technical research.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, PolyPid's story centers on execution following a potential regulatory approval. If D-PLEX100 is cleared, the company's priority shifts to a successful early-2027 U.S. launch with Azurity, initial revenue generation, and establishing real-world adoption among surgeons and hospitals. Consensus revenue expectations imply a meaningful step-up in 2026, though projections for the following year suggest the market is still calibrating the pace and durability of commercialization.

Longer term, several themes merit attention. Margin sustainability will depend on the economics of the Azurity arrangement and manufacturing efficiency as volumes scale. Market expansion opportunities include the European submission and potential label extensions into additional surgical or infection-prevention indications. Competitive threats could emerge from alternative infection-prevention approaches, underscoring the importance of demonstrating clear clinical and economic value. Capital allocation priorities — balancing milestone inflows against continued research and development investment — will be pivotal in determining whether the company can fund pipeline expansion without excessive dilution. As always, these factors are reflected in analyst expectations rather than in any single forecast, and the wide range of published price targets underscores the inherent uncertainty of a pre-commercial biotech nearing its most consequential milestone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

PYPD is expected to report earnings to rise 55.71% to -37 cents per share on February 10

PolyPid Ltd PYPD Stock Earnings Reports
Q4'26
Est.
$-0.37
Q3'26
Missed
by $0.70
Q2'26
Beat
by $0.05
Q1'26
Beat
by $0.70
Q4'25
Missed
by $0.08
The last earnings report on November 11 showed earnings per share of -23 cents, missing the estimate of 46 cents. With 137.84K shares outstanding, the current market capitalization sits at 124.71M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LABX4.340.36
+9.05%
Tradr 2X Long ALAB Daily ETF (LABX)
AMKL2.430.01
+0.41%
Defiance Daily Target 2X Long AMKR ETF (AMKL)
IBMS25.44-0.09
-0.37%
iShares iBonds Dec 2030 Term Muni Bond ETF (IBMS)
MKOR47.12-0.43
-0.90%
Matthews Korea Active ETF (MKOR)
IDEQ32.48-0.38
-1.16%
Lazard Active ETF TR

PYPD and Stocks

Correlation & Price change

A.I.dvisor tells us that PYPD and BCYC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and BCYC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYPD
1D Price
Change %
PYPD100%
+6.34%
BCYC - PYPD
31%
Poorly correlated
+0.63%
TSHA - PYPD
31%
Poorly correlated
-1.48%
IDYA - PYPD
29%
Poorly correlated
-9.75%
AMLX - PYPD
29%
Poorly correlated
-1.01%
SYRE - PYPD
29%
Poorly correlated
-5.60%
More
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes

Industry Biotechnology

Industry
N/A
Address
18 Hasivim Street
Phone
+972 747195700
Employees
75
Web
https://www.polypid.com
PolyPid Ltd. (PYPD) Stock Forecast: The FDA Decision That Could Define Its Commercial Future